79 related articles for article (PubMed ID: 18036687)
21. Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer.
Zhu J; Li X; Shen Y; Guan Y; Gu W; Lian P; Sheng W; Cai S; Zhang Z
Radiother Oncol; 2018 Oct; 129(1):143-148. PubMed ID: 29273261
[TBL] [Abstract][Full Text] [Related]
22. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
Arredondo J; Baixauli J; Beorlegui C; Arbea L; Rodríguez J; Sola JJ; Chopitea A; Hernández-Lizoáin JL
Dis Colon Rectum; 2013 Apr; 56(4):416-21. PubMed ID: 23478608
[TBL] [Abstract][Full Text] [Related]
23. [Phase I study of postoperative concurrent chemoradiation with capecitabine as adjuvant treatment for stage II/III operable rectal cancer].
Jin J; Li YX; Liu YP; Wang WH; Li T; Li N; Song YW
Zhonghua Zhong Liu Za Zhi; 2006 May; 28(5):393-6. PubMed ID: 17045010
[TBL] [Abstract][Full Text] [Related]
24. Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial.
Eisterer W; De Vries A; Öfner D; Rabl H; Koplmüller R; Greil R; Tschmelitsch J; Schmid R; Kapp K; Lukas P; Sedlmayer F; Höfler G; Gnant M; Thaler J;
Anticancer Res; 2014 Nov; 34(11):6767-73. PubMed ID: 25368289
[TBL] [Abstract][Full Text] [Related]
25. Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial.
Li JL; Ji JF; Cai Y; Li XF; Li YH; Wu H; Xu B; Dou FY; Li ZY; Bu ZD; Wu AW; Tham IW
Radiother Oncol; 2012 Jan; 102(1):4-9. PubMed ID: 21903285
[TBL] [Abstract][Full Text] [Related]
26. Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy.
Schwaab J; Horisberger K; Ströbel P; Bohn B; Gencer D; Kähler G; Kienle P; Post S; Wenz F; Hofmann WK; Hofheinz RD; Erben P
BMC Cancer; 2011 Aug; 11():363. PubMed ID: 21854597
[TBL] [Abstract][Full Text] [Related]
27. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
[TBL] [Abstract][Full Text] [Related]
28. A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.
Delord JP; Pierga JY; Dieras V; Bertheault-Cvitkovic F; Turpin FL; Lokiec F; Lochon I; Chatelut E; Canal P; Guimbaud R; Mery-Mignard D; Cornen X; Mouri Z; Bugat R
Br J Cancer; 2005 Mar; 92(5):820-6. PubMed ID: 15756252
[TBL] [Abstract][Full Text] [Related]
29. Acute small-bowel toxicity during neoadjuvant combined radiochemotherapy in locally advanced rectal cancer: determination of optimal dose-volume cut-off value predicting grade 2-3 diarrhoea.
Reis T; Khazzaka E; Welzel G; Wenz F; Hofheinz RD; Mai S
Radiat Oncol; 2015 Jan; 10():30. PubMed ID: 25636703
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
Velenik V; Ocvirk J; Oblak I; Anderluh F
Eur J Surg Oncol; 2010 Mar; 36(3):244-50. PubMed ID: 20042310
[TBL] [Abstract][Full Text] [Related]
31. Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer.
Zampino MG; Magni E; Leonardi MC; Petazzi E; Santoro L; Luca F; Chiappa A; Petralia G; Trovato C; Fazio N; Orecchia R; Nolè F; de Braud F
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):421-7. PubMed ID: 19211200
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
Dunst J; Debus J; Rudat V; Wulf J; Budach W; Hoelscher T; Reese T; Mose S; Roedel C; Zuehlke H; Hinke A
Strahlenther Onkol; 2008 Sep; 184(9):450-6. PubMed ID: 19016023
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
Gao YH; An X; Sun WJ; Cai J; Cai MY; Kong LH; Lin JZ; Liu GC; Tang JH; Wu XJ; Chen G; Pan ZZ; Ding PR
J Surg Oncol; 2014 Apr; 109(5):478-82. PubMed ID: 24288203
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
[TBL] [Abstract][Full Text] [Related]
35. Combined-modality therapy of rectal cancer with irinotecan-based regimens.
Minsky BD
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):49-55. PubMed ID: 15685836
[TBL] [Abstract][Full Text] [Related]
36. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
Kato T; Mishima H; Ikenaga M; Murata K; Ishida H; Fukunaga M; Ota H; Tominaga S; Ohnishi T; Amano M; Ikeda K; Ikeda M; Sekimoto M; Sakamoto J; Monden M
Cancer Chemother Pharmacol; 2008 Feb; 61(2):275-81. PubMed ID: 17429630
[TBL] [Abstract][Full Text] [Related]
38. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis.
Das P; Lin EH; Bhatia S; Skibber JM; Rodriguez-Bigas MA; Feig BW; Chang GJ; Hoff PM; Eng C; Wolff RA; Delclos ME; Krishnan S; Janjan NA; Crane CH
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1378-83. PubMed ID: 17056196
[TBL] [Abstract][Full Text] [Related]
39. Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer.
Park JH; Yoon SM; Yu CS; Kim JH; Kim TW; Kim JC
Cancer; 2011 Aug; 117(16):3703-12. PubMed ID: 21328328
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Dunst J; Reese T; Sutter T; Zühlke H; Hinke A; Kölling-Schlebusch K; Frings S
J Clin Oncol; 2002 Oct; 20(19):3983-91. PubMed ID: 12351595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
